Get started
ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

LLY trade ideas

Zepbound's FDA Approval: Boosting Lilly & Co's Stock OutlookThe FDA has approved a new drug, Zepbound, from Lilly (Eli) & Co, which will be used to treat obesity. According to the World Health Organization, nearly 3 million people die from obesity annually worldwide. Therefore, Zepbound is expected to be in demand, allowing the issuer to increase its revenue while maintaining current profitability levels. According to Morgan Stanley, the global market for obesity treatment drugs was valued at USD 2.4 billion in 2022 and is expected to reach USD 77 billion by 2030. Today, we are focusing on the stock chart of Lilly (Eli) & Co. (LLY). On the D1 timeframe, a support level has formed at 567.18 and resistance at 625.87. A relatively wide channel has developed, with a high probability of breaking through the upper boundary. The issuer's quotes are aiming to reach a historical maximum. In the event of a channel breakout to its width, the target could be the mark of 684.56. Additionally, following the last meeting of the US Federal Reserve, investors expect a softening of monetary policy, which is conducive to stock market growth. On the H1 timeframe, long positions from current positions with a target of 625.87 may be of interest. A long position can be held up to 684.56 in the medium term, while the consolidation of quotes above the level of 597.70 will be an important signal for the continuation of the upward trend. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:LLY
by RoboMarkets
LLY Eli Lilly: $555 | a look into an Outperformerfundamentally sound as it addresses world problems in the field of science medicine it acquires great companies to grow its portfolio and price wise lets investors get out at premium yet provides ample time to those who are patient to accumulate during down years impressive board leadership is topnotch if you missed the bottom and fomo in at the top or highs be ready to sit on for 3 to 7 years to break even as such an established cycle according to weather and healthcare
NYSE:LLY
by senyor
2
ELI LILLY targeting $705.00 if the 1D MA100 holds.Eli Lilly (LLY) has been on an incredible run ever since our March 01 buy signal (see chart below) that even broke above Channel Up: We have been strong supporters of the company's fundamentals and those are translated into strong technical bullish patters, offering solid buy opportunities. Another such opportunity exists now as the price is trading around the 1D MA50 (blue trend-line) near the bottom of the 2023 Channel Up. As long as the 1D MA100 (green trend-line), which is exactly on the Channel's bottom, holds, we remain bullish, targeting the 2.382 Fibonacci extension (similar to the May 22 High) at $705.00. If the 1D MA100 breaks though, we will take the loss and sell instead targeting the 1D MA200 (orange trend-line) at $500.00 where a stronger buy opportunity exists. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
ELI LILLY Expected to rally above 700 if these conditions hold.LLY is holding the 1D MA50 on a neutral 1D technical outlook (RSI = 47.021, MACD = 2.060, ADX = 24.740), which indicates a strong demand level for the stock. The 1D RSI which is under a LH trendline shows that the stock price is at a pre bullish breakout accumulation like the last week of July and early August. If it holds the line, we will buy and aim a +30% rise (TP = 710.00), following a regression of -8% on each top. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
1
LLY's Market Direction- which path will we take?NYSE:LLY is a high performing company and my single largest holding. LLY has an incredible pipeline and a strong management team. The GLP1 weight loss medications have undeniable near term and long term potential, and there is strong optimism for the Alzheimer treatment in LLY's pipeline. We need to remain objective to the possibility that the market has priced this in and that the strong uptrend may be ready for a breather. This overview will focus on potential for further upside and where we may have opportunities for additional accumulation. I am not taking additional profit at this time due to my long term active management of this position. For the sake of transparency, I manage 70% of this position using trends on the weekly chart and the remaining 30% using a daily time frame. Looking at the weekly chart, we see sentiment peaking and a second bearish divergence in RSI in early October followed by a MACD cross over at the end of October. There is persistent symmetry in the primary uptrend as well as a series of secondary downtrends. We can make a strong argument for the formation in of a bear flag or diamond top following September. Noting the channel, key fib levels, and the volume weighted average prices anchored to the breakout from March low and the start of consolidation in May suggest supporting levels near 550, 535, and 487. A fib extension from September high to October low suggests overhead levels of 655 and 687, contingent on a weekly close above 615-625. Note that trend has aligned to the fib time zone anchored to the December 2021 high. The next key time zone is 12/11/23. Looking at the daily we can see a clear loss in momentum in both the short term derivative oscillator and the long term William's oscillator. Price has fallen through the VWAPs anchored to the October high and low. Next supporting VWAPs are anchored to September high and the August gap up. The latter is trending in line with the current rising wedge. These imply key supporting levels at 580 and 568. For a potential continuation, I'd like to see a full candle close above the 612-616 range. This closely aligns to what we see in the weekly chart. Otherwise, a retest of 615 and that overhead resistance will lead me to look for a break below the rising wedge. This would suggest downside targets of 555 and 535. These align with key Fibonacci levels, the VWAP anchored to the May gap up, and a proportional measured range from the middle of the descending wedge. Note possibility for trend to align with the fib time zone with the next key dates marked at 11/17, 12/5, and 12/19. Finally, while recent trend opens the possibility of a near term reversal, the history of strong seasonal performance in the months of November and December should not be ignored. The pharmacy sector ETF NASDAQ:PPH shows December closing higher 75% of the time with an average gain of 1.4% over the past 20 years; the second highest performing month next to April. December has been the strongest performing month for LLY; closing higher 75% of the time with an average gain of 4.7%
NYSE:LLYLong
by Ben_1148x2
3
Eli Lilly and Company (LLY) - A Comprehensive OverviewOverview: Eli Lilly and Company, a global pharmaceutical leader, is known for its extensive range of human pharmaceuticals. Founded in 1876 and headquartered in Indianapolis, LLY focuses on discovering, developing, and marketing pharmaceuticals worldwide. Key Financials: As of December 31, 2022, LLY's total assets stood at $49.49 billion, with a significant portion in current assets ($18.03 billion) and non-current assets ($31.45 billion). Net sales/revenue saw a steady increase from $24.55 billion in 2018 to $28.54 billion in 2022. Gross profit also rose from $19.59 billion in 2018 to $23.31 billion in 2022. Net income displayed notable growth, especially in 2022, with $6.25 billion compared to $3.23 billion in 2018. LLY’s operating cash flow improved from $5.53 billion in 2018 to $7.08 billion in 2022. Stock Performance: The stock price as of November 10, 2023, was $597.71, with a 52-week high of $629.97. Market Capitalization: $537.5 billion. The EPS growth was +14.7% from the prior TTM. Market Position Against Competitors: LLY’s P/E ratio of 83.1 is significantly higher compared to industry peers like Johnson & Johnson (JNJ), Pfizer Inc. (PFE), Merck & Co Inc (MRK), and Bristol-Myers Squibb Co (BMY), indicating a potentially higher growth expectation from the market. LLY's Price to Sales ratio is 18.2, showing a premium valuation compared to its competitors. Revenue growth at +1.5% is moderate compared to industry growth rates. Investor Sentiment: The Equity Summary Score for LLY is neutral at 6.3, reflecting a balanced view among analysts. Analysts’ opinions show a mix of Neutral and Buy, with a significant positive outlook from firms like Jefferies, CSFB, and UBS. Conclusion: Eli Lilly and Company, with its strong financials, diverse product portfolio, and robust operational efficiency, remains a key player in the pharmaceutical industry. While it commands a premium valuation compared to its competitors, its consistent growth in key financial metrics, and innovative product pipeline, position it favorably for future growth. Investors and analysts maintain a cautiously optimistic view of the company's prospects in a competitive market.
NYSE:LLYLong
by thedailyinvestor
Earnings 11-2Earnings does not look as if analysts expect a whole awful lot but you never know! M pattern that could take this lower. Peak 2 is higher than peak 1 so possibly looking at a Shark (to the .886 or the 1.113 or a Cypher (to the .786 and measured from entire structure and the Shark is measured from the 1st peak) This could also be a NEN-Star (takes it to the 1.272.) and I will not venture a guess at this time. Bearish RSI divergence (purple line). Looks to me like this party will end within a few weeks but who knows. Possibly a 2nd shoulder will form wile folks run for the life boat. ); No recommendation 52 Week Range 302.14 629.97 Day Range 556.64 570.81 EPS (FWD) 8.24 PE (FWD) 68.03 Div Rate (FWD) $4.52 Yield (FWD) 0.81% Short Interest 0.71% Market Cap $503.81B Volume 2,717,360
NYSE:LLY
by lauralea
2
Eli Lilly Sues Online Pharmacy To Ban US Imports Of Fake drugs Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro. Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is expected to be approved for weight loss later this year. The Indianapolis-based drugmaker said the suit will go to the U.S. International Trade Commission (ITC). It names the U.S.-based Artic Peptides, Strate Labs, Supopeptide, The Triggered Brand, and Unewlife as defendants, along with Britain’s Biolabshop, Spain’s Super Human Store and Steroide Kaufen in Poland. China’s Audrey Beauty, Mew Mews Company and AustroPeptide were also targeted in the complaint. Lilly said testing of AustroPeptide’s product purporting to contain the Mounjaro main ingredient tirzepatide showed it actually was “nothing more than sugar alcohol.” The U.S. ITC has the power issue import bans against products that violate certain parts of U.S. trade law and to take them off the market once they have entered the country. Once the complaint is published in the Federal Register, the commission will have 30 days to decide whether to accept it or not. Lilly is accusing the online pharmacies of infringing its trademark for Mounjaro, falsely associating themselves with Lilly and approved tirzepatide, and making false or misleading statements in their advertisements related to tirzepatide. “The unapproved drug products are dangerous research chemicals that are not approved for human consumption and have no connection to Eli Lilly or Mounjaro,” Lilly said in its lawsuit. Lilly is the only company with U.S. Food and Drug Administration approval to sell tirzepatide products.
NYSE:LLYLong
by DEXWireNews
Weight loss - Stock GainEli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as diabetes, oncology, immunology, neuroscience, and other medical conditions. One notable aspect of their recent success is the introduction of a weight loss drug, tirzepatide. This drug is similar to other medications like Ozempic and Wegovy, which are also designed to help with weight loss. These medications are administered via weekly injections and work by affecting the patient's appetite by mimicking certain hormones in the gut. Wegovy, for instance, primarily mimics the hunger-regulating hormone called GLP-1, while tirzepatide goes a step further by mimicking both GLP-1 and another hormone called GIP. These hormonal effects can lead to decreased appetite, making it easier for individuals to manage their weight.
NYSE:LLYLong
by Helios_Capital_Investment
ELI LILLY Our gem on the verge of making a paradigm shift.Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May. This time the price reversed much quicker than technically expected and is attempting again to break the top (Higher Lows trend-line) of the Channel Up that started in 2020. If it closes above it, then we wil target the 3.0 Fibonacci Channel extension at $700. If it gets rejected and stays within the Channel Up, we will sell and target the recent Support at $520. Note that a break above this 3-year Channel Up may constitute a paradigm shift as the stock has never hit a new upper Fibonacci level that quickly (remember it broke above the 2.0 Fib just 5 months ago). This can transcend LLY into an even more aggressive bullish nature that we can't yet quantify. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
LLY Bubble May Be FinishedHello friends. Eli Lilly has been catapulted into an extraordinary bubble, spurred on by the narrative of their weight loss drug being taken up by America's obese population. The price just seems to go up and up forever, and many traders likely think that it will go to infinity. But all bubbles must pop at some point, and we think that it's the perfect time for the Eli Lilly bubble to come to an end right about now. We have found that one of the best ways to get in on the collapse of a bubble is not to short the pico-top, but rather to have some patience, and wait for a peak followed by a sharp impulsive looking movement to the downside, and then a corrective pullback to that move. Finally, we can short. This is what Eli Lilly looks like right now for us. According to our view of the wave count, we could expect an impulsive wave 3 downwards, which would be a very big and volatile move down. As a result, the best way of trading this is to buy puts on LLY expiring in around 45 days. It's a risky trade that could get wiped out entirely, or could make a huge profit. We will see! Thanks for playing.
NYSE:LLYShort
by bowtrix
4
ELI LILLY Needs to correct a little more. Massive buy after.Eli Lilly has completed 3 red weeks in a row. The parabolic rise it is seeing for years is seen accurately on this Fibonacci Channel. Every such price peak, pulled back to under the MA100 (1d), which is now at 492.43, in order to gather buyers. Trading Plan: 1. Sell on the current market price. Targets: 1. 490 (between the MA100 (1d) and the Fibonacci 2.0 level. Tips: 1. The MACD (1d) is just formed a Sell Cross. Only once since 2018 has a Sell Cross failed to deliver a sizeable drop. Please like, follow and comment!!
NYSE:LLYShort
by TradingBrokersView
1
ELI LILLY: Possible to start a strong multi week correction.Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is now correcting. The rejection took place at the top of the Channel Up. This is a hint that investors should be exiting LLY and not entering. Historically the most efficient level to buy is on the 1W MA50 with a max extension to the 1W MA100. That is our entry strategy. Don't take chances and take the best possible entry. This stock will reward us enormously in 2024. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYShort
by InvestingScope
4
LLY, This ALL-TIME-HIGH ROCKET is a NEVER ENDING STORY!Hello There! Welcome to my new analysis about LLY on several timeframe perspectives. LLY printed an major bullish breakout literally over night bouncing out of the range. In the recent times the pharma industry transformed into a eager bullish environment since the gains seen because of the "pandemic" and LLY is a stock already present since 1978 in the 19th century, a time before the great depression. The FED is considering a more dovish policy as inflationary pressures in the U.S. decreased and LLY showed an development typical for more bullish stocks within the market, it already bounced before the U.S. CPI release signaled an easing in inflation, such moves are always important to anticipate as it is the case with LLY and the long direction. Within the chart LLY is now forming a flag-formation on the local term which is likely to complete with a breakout in the near future setting up the next wave C extension into the upper directions. On the global term LLY bounced several times within the ascending trendline and has an underlying strong volatility-spike structure which is bolstering the bullish sentiment here. Once LLY has shown up with the breakout dynamics and reached the targets of the local formation this is likely to convert into the continuation of the global trend as well. Currently, the bullish scenario should be considered if the FED does not become more hawkish on interest rates or there is a major demand shortage increasing supply within the pharma market this should be a considerable scenario for the next times. In this manner, thank you everybody for watching, support is greatly appreciated, all the best! VP
NYSE:LLY
by VincePrince
4
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking above the August 16 2021 High. As last week's 1W candle closed in red (the first after 5 straight bullish weeks) this is considered so far a Higher Highs rejection and calls for an early sell signals towards the end of October, targeting the 1D MA100 (red trend-line) at $500.00, where the stock will start turning into a buy opportunity again (assuming the RSI is below 55.00). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYShort
by TradingShot
$LLY, Price correction?Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Positive: Yields high return on invested capital Has raised its dividend for 8 consecutive years 13 analysts have revised their earnings upwards for the upcoming period Prominent player in the Pharmaceuticals industry Cash flows can sufficiently cover interest payments High return over the last year An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00. Negative: Trading at a high earnings multiple Corporate insiders Sold shares worth $21.3B in the past 3 months Hedge funds Sold 789.5K shares in the past quarter Very strong bullish trend, it is expecting a price correction after this stock should follow
NYSE:LLY
by SANMARTIN_M
1